Quantcast

Latest Triptorelin Stories

2014-01-13 12:28:06

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg. Debiopharm is investigating the efficacy and safety of...

2011-05-16 10:02:00

WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E. David Crawford, MD, head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center in Denver, and lead study investigator. The full manuscript has just been accepted and will be...

2010-10-27 17:27:00

NEW YORK, Oct. 27 /PRNewswire/ -- Drugs, known as gonadotropin-releasing hormone (GnRH) agonists, may raise diabetes and heart risk and, as a result, now need new warnings. U.S. health officials said the drug used to stem the production of testosterone, the hormone that contributes to prostate cancer growth, could also lead to sudden death. "The risk of diabetes, heart disease and sudden death in men undergoing prostate cancer treatment with these drugs does not appear to be elevated,...

2010-06-01 15:30:00

SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr. Judd Moul, Chief of the Division of Urology at Duke University Health Science Center. Dr. Moul was joined at the...

2010-05-03 10:37:00

Preliminary review suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists SILVER SPRING, Md., May 3 /PRNewswire-USNewswire/ -- Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related